{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:26:39Z","timestamp":1793967999016,"version":"4.8.0"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008065","name":"Georgia Research Alliance","doi-asserted-by":"publisher","award":["GRA.VL24.C10"],"award-info":[{"award-number":["GRA.VL24.C10"]}],"id":[{"id":"10.13039\/100008065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SORSCH21XX0"],"award-info":[{"award-number":["SORSCH21XX0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Drug Discov."],"DOI":"10.1038\/s44386-025-00026-1","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:33:10Z","timestamp":1762144390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A novel drug series optimized to address cystic fibrosis and other CFTR deficiency diseases of human airways"],"prefix":"10.1038","volume":"2","author":[{"given":"Andras","family":"Rab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candela","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhana","family":"Ponnaluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Kolykhalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huw M. L.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Sorscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"26_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1126\/science.aaw0553","volume":"365","author":"C Manfredi","year":"2019","unstructured":"Manfredi, C., Tindall, J. M., Hong, J. S. & Sorscher, E. J. Making precision medicine personal for cystic fibrosis. Science 365, 220\u2013221 (2019).","journal-title":"Science"},{"key":"26_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell, S. C. et al. The future of cystic fibrosis care: a global perspective. Lancet Respir. Med. 8, 65\u2013124 (2020).","journal-title":"Lancet Respir. Med."},{"key":"26_CR3","doi-asserted-by":"crossref","unstructured":"Shteinberg, M. and Taylor-Cousar, J. L. Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease. Eur. Respir. Rev. 29, 190112 (2020).","DOI":"10.1183\/16000617.0112-2019"},{"key":"26_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","volume":"18","author":"JP Clancy","year":"2019","unstructured":"Clancy, J. P. et al. CFTR modulator theratyping: Current status, gaps and future directions. J. Cyst. Fibros 18, 22\u201334 (2019).","journal-title":"J. Cyst. Fibros"},{"key":"26_CR5","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","volume":"199","author":"AF McCague","year":"2019","unstructured":"McCague, A. F. et al. Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis. Am. J. Respir. Crit. Care Med. 199, 1116\u20131126 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"26_CR6","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMra2216474","volume":"389","author":"H Grasemann","year":"2023","unstructured":"Grasemann, H. & Ratjen, F. Cystic fibrosis. N. Engl. J. Med. 389, 1693\u20131707 (2023).","journal-title":"N. Engl. J. Med."},{"key":"26_CR7","unstructured":"Sorscher, E. J. Cystic fibrosis. In Harrison\u2019s Principles of Internal Medicine(ed. Jameson, J. L. et al.) (McGraw-Hill Education\/Medical, New York, NY, 2022)."},{"key":"26_CR8","unstructured":"Drugs.com. FDA approves Alyftrek. https:\/\/www.drugs.com (2024)."},{"key":"26_CR9","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating, D. et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379, 1612\u20131620 (2018).","journal-title":"N. Engl. J. Med."},{"key":"26_CR10","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton, P. G. et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N. Engl. J. Med. 381, 1809\u20131819 (2019).","journal-title":"N. Engl. J. Med."},{"key":"26_CR11","unstructured":"TRIKAFTA [prescribing information]. (Vertex Pharmaceuticals Incorporated, Boston, MA, 2020)."},{"key":"26_CR12","unstructured":"CFF. FDA Approves Trikafta for 94 Additional Rare CFTR Mutations. https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-us-fda-approval-trikafta (2024)."},{"key":"26_CR13","unstructured":"CFF. Drug Development Pipeline. https:\/\/www.pfizer.com\/science\/drug-product-pipeline (2021)."},{"key":"26_CR14","unstructured":"Sionna. Sionna Therapeutics Launches With $\u2009111\u2009Million Series B Financing To Advance Pipelinee Of Novel Small Molecules With The Potential To Fully Restore Cftr Function In Cystic Fibrosis. https:\/\/www.prnewswire.com\/news-releases (2022)."},{"key":"26_CR15","volume":"10","author":"V Marchesin","year":"2024","unstructured":"Marchesin, V. et al. A uniquely efficacious type of CFTR corrector with complementary mode of action. SciAdv. 10, eadk1814 (2024).","journal-title":"SciAdv."},{"key":"26_CR16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jcf.2024.02.006","volume":"23","author":"H Bihler","year":"2024","unstructured":"Bihler, H. et al. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis. J. Cyst. Fibros 23, 664\u2013675 (2024).","journal-title":"J. Cyst. Fibros"},{"key":"26_CR17","doi-asserted-by":"crossref","unstructured":"Han, S. T. et al. Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators. JCI Insight 3, e121159 (2018).","DOI":"10.1172\/jci.insight.121159"},{"key":"26_CR18","doi-asserted-by":"crossref","unstructured":"Sabusap, C. M. et al. Analysis of cystic fibrosis-associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseases. JCI Insight 1, e86581 (2016).","DOI":"10.1172\/jci.insight.86581"},{"key":"26_CR19","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/ng.2745","volume":"45","author":"PR Sosnay","year":"2013","unstructured":"Sosnay, P. R. et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat. Genet 45, 1160\u20137 (2013).","journal-title":"Nat. Genet"},{"key":"26_CR20","unstructured":"Millen, L. et al. Theratyping 2019. Pediatr. Pulmonol. 54, 2300110 (2019)."},{"key":"26_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","volume":"15","author":"AG Durmowicz","year":"2018","unstructured":"Durmowicz, A. G., Lim, R., Rogers, H., Rosebraugh, C. J. & Chowdhury, B. A. The U.S. Food and Drug administration\u2019s experience with ivacaftor in cystic fibrosis. establishing efficacy using in vitro data in lieu of a clinical trial. Ann. Am. Thorac. Soc. 15, 1\u20132 (2018).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"26_CR22","first-page":"29","volume":"79","author":"C Le","year":"2016","unstructured":"Le, C., McCrary, H. C. & Chang, E. Cystic fibrosis sinusitis. Adv. Otorhinolaryngol. 79, 29\u201337 (2016).","journal-title":"Adv. Otorhinolaryngol."},{"key":"26_CR23","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jaip.2016.04.013","volume":"4","author":"DL Hamilos","year":"2016","unstructured":"Hamilos, D. L. Chronic rhinosinusitis in patients with cystic fibrosis. J. Allergy Clin. Immunol. Pract. 4, 605\u201312 (2016).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"26_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/1945892420912368","volume":"34","author":"SE Lee","year":"2020","unstructured":"Lee, S. E. et al. Cystic fibrosis transmembrane conductance regulator modulator therapy: a review for the otolaryngologist. Am. J. Rhinol. Allergy 34, 573\u2013580 (2020).","journal-title":"Am. J. Rhinol. Allergy"},{"key":"26_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ijporl.2019.05.034","volume":"124","author":"AS Lowery","year":"2019","unstructured":"Lowery, A. S. et al. Chronic rhino-sinusitis treatment in children with cystic fibrosis: a cross-sectional survey of pediatric pulmonologists and otolaryngologists. Int. J. Pediatr. Otorhinolaryngo.l 124, 139\u2013142 (2019).","journal-title":"Int. J. Pediatr. Otorhinolaryngo.l"},{"key":"26_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/alr.21252","volume":"4","author":"EH Chang","year":"2014","unstructured":"Chang, E. H. New insights into the pathogenesis of cystic fibrosis sinusitis. Int. Forum Allergy Rhinol. 4, 132\u20137 (2014).","journal-title":"Int. Forum Allergy Rhinol."},{"key":"26_CR27","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/thx.2008.112870","volume":"64","author":"MR Loebinger","year":"2009","unstructured":"Loebinger, M. R., Bilton, D. & Wilson, R. Upper airway 2: Bronchiectasis, cystic fibrosis and sinusitis. Thorax 64, 1096\u2013101 (2009).","journal-title":"Thorax"},{"key":"26_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/MOO.0000000000000596","volume":"28","author":"MT Chang","year":"2020","unstructured":"Chang, M. T. & Patel, Z. M. Update on long-term outcomes for chronic rhinosinusitis in cystic fibrosis. Curr. Opin. Otolaryngol. Head Neck Surg. 28, 46\u201351 (2020).","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"key":"26_CR29","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/alr.22332","volume":"9","author":"AC Zemke","year":"2019","unstructured":"Zemke, A. C. et al. Clinical predictors of cystic fibrosis chronic rhinosinusitis severity. Int. Forum. Allergy Rhinol. 9, 759\u2013765 (2019).","journal-title":"Int. Forum. Allergy Rhinol."},{"key":"26_CR30","doi-asserted-by":"publisher","first-page":"e0235638","DOI":"10.1371\/journal.pone.0235638","volume":"15","author":"R Gostelie","year":"2020","unstructured":"Gostelie, R. et al. The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients. PLoS One 15, e0235638 (2020).","journal-title":"PLoS One"},{"key":"26_CR31","unstructured":"Henig, N. Sinusitis and cystic fibrosis. Vol. 2021 (Stanford Medicine, The Cystic Fibrosis Center at Stanford)."},{"key":"26_CR32","unstructured":"Sorscher, E. Cystic fibrosis: embracing risk and inspiration. In Plenary Address, CF Foundation Invitational Research Conference (Stowe, VT, 2024)."},{"key":"26_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107873","volume":"300","author":"A Della Sala","year":"2024","unstructured":"Della Sala, A. et al. A nonnatural peptide targeting the A-kinase anchoring function of PI3K\u03b3 for therapeutic cAMP modulation in pulmonary cells. J. Biol. Chem. 300, 107873 (2024).","journal-title":"J. Biol. Chem."},{"key":"26_CR34","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1055\/s-0039-1697639","volume":"40","author":"B Garcia","year":"2019","unstructured":"Garcia, B. & Flume, P. A. Pulmonary complications of cystic f.ibrosis. Semin. Respir. Crit. Care Med. 40, 804\u2013809 (2019).","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"26_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07504-1","volume":"7","author":"IM Pranke","year":"2017","unstructured":"Pranke, I. M. et al. Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators. Sci. Rep. 7, 7375 (2017).","journal-title":"Sci. Rep."},{"key":"26_CR36","doi-asserted-by":"crossref","unstructured":"Keegan, D. E. & Brewington, J. J. Nasal epithelial cell-based models for individualized study in cystic fibrosis. Int. J. Mol. Sci. 22, 4448 (2021).","DOI":"10.3390\/ijms22094448"},{"key":"26_CR37","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","volume":"106","author":"F Van Goor","year":"2009","unstructured":"Van Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. USA 106, 18825\u201330 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"26_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-1-61779-117-8_4","volume":"741","author":"T Neuberger","year":"2011","unstructured":"Neuberger, T., Burton, B., Clark, H. & Van Goor, F. Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators. Methods Mol. Biol. 741, 39\u201354 (2011).","journal-title":"Methods Mol. Biol."},{"key":"26_CR39","doi-asserted-by":"crossref","unstructured":"Safi, C., Zheng, Z., Dimango, E., Keating, C. & Gudis, D. A. Chronic rhinosinusitis in cystic fibrosis: diagnosis and medical management. Med. Sci. (Basel) 7, 32 (2019).","DOI":"10.3390\/medsci7020032"},{"key":"26_CR40","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S1569-1993(13)00150-1","volume":"12","author":"K Aan\u00e6s","year":"2013","unstructured":"Aan\u00e6s, K. Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis. J. Cyst. Fibros 12, S1\u201320 (2013).","journal-title":"J. Cyst. Fibros"},{"key":"26_CR41","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/lio2.401","volume":"5","author":"BJ Johnson","year":"2020","unstructured":"Johnson, B. J., Choby, G. W. & O\u2019Brien, E. K. Chronic rhinosinusitis in patients with cystic fibrosis-Current management and new treatments. Laryngoscope Investig. Otolaryngol. 5, 368\u2013374 (2020).","journal-title":"Laryngoscope Investig. Otolaryngol."},{"key":"26_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5780","volume":"5","author":"JL Fothergill","year":"2014","unstructured":"Fothergill, J. L., Neill, D. R., Loman, N., Winstanley, C. & Kadioglu, A. Pseudomonas aeruginosa adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs. Nat. Commun. 5, 4780 (2014).","journal-title":"Nat. Commun."},{"key":"26_CR43","doi-asserted-by":"publisher","unstructured":"Armbruster, C. R. et al. Evolution and adaptation of Pseudomonas aeruginosa in the paranasal sinuses of people with cystic fibrosis. bioRxiv https:\/\/doi.org\/10.1101\/2020.10.29.359844 (2020).","DOI":"10.1101\/2020.10.29.359844"},{"key":"26_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0165-5876(01)00556-0","volume":"61","author":"KW Rosbe","year":"2001","unstructured":"Rosbe, K. W., Jones, D. T., Rahbar, R., Lahiri, T. & Auerbach, A. D. Endoscopic sinus surgery in cystic fibrosis: do patients benefit from surgery?. Int. J. Pediatr. Otorhinolaryngol. 61, 113\u20139 (2001).","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"26_CR45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/alr.22043","volume":"8","author":"J Nelson","year":"2018","unstructured":"Nelson, J., Karempelis, P., Dunitz, J., Hunter, R. & Boyer, H. Pulmonary aspiration of sinus secretions in patients with cystic fibrosis. Int Forum. Allergy Rhinol. 8, 385\u2013388 (2018).","journal-title":"Int Forum. Allergy Rhinol."},{"key":"26_CR46","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00405-019-05308-9","volume":"276","author":"P Luparello","year":"2019","unstructured":"Luparello, P. et al. Outcomes of endoscopic sinus surgery in adult lung transplant patients with cystic fibrosis. Eur. Arch. Otorhinolaryngol. 276, 1341\u20131347 (2019).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"26_CR47","first-page":"378","volume":"22","author":"RG Bopaka","year":"2015","unstructured":"Bopaka, R. G., El Khattabi, W., Janah, H., Jabri, H. & Afif, H. Bronchiectasis: a bacteriological profile. Pan. Afr. Med. J. 22, 378 (2015).","journal-title":"Pan. Afr. Med. J."},{"key":"26_CR48","doi-asserted-by":"crossref","unstructured":"Maselli, D. J., Amalakuhan, B., Keyt, H. & Diaz, A. A. Suspecting non-cystic fibrosis bronchiectasis: What the busy primary care clinician needs to know. Int. J. Clin. Pract. 71, e12924 (2017).","DOI":"10.1111\/ijcp.12924"},{"key":"26_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-018-0042-3","volume":"4","author":"JD Chalmers","year":"2018","unstructured":"Chalmers, J. D., Chang, A. B., Chotirmall, S. H., Dhar, R. & McShane, P. J. Bronchiectasis. Nat. Rev. Dis. Primers 4, 45 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"26_CR50","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","volume":"392","author":"PA Flume","year":"2018","unstructured":"Flume, P. A., Chalmers, J. D. & Olivier, K. N. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet 392, 880\u2013890 (2018).","journal-title":"Lancet"},{"key":"26_CR51","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1073\/pnas.1914912117","volume":"117","author":"AC Miller","year":"2020","unstructured":"Miller, A. C. et al. Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. Proc. Natl. Acad. Sci. USA 117, 1621\u20131627 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"26_CR52","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/hmg\/4.4.635","volume":"4","author":"PF Pignatti","year":"1995","unstructured":"Pignatti, P. F., Bombieri, C., Marigo, C., Benetazzo, M. & Luisetti, M. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum. Mol. Genet 4, 635\u20139 (1995).","journal-title":"Hum. Mol. Genet"},{"key":"26_CR53","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.0009-9163.2004.00265.x","volume":"65","author":"T Casals","year":"2004","unstructured":"Casals, T. et al. Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations?. Clin. Genet 65, 490\u20135 (2004).","journal-title":"Clin. Genet"},{"key":"26_CR54","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1164\/rccm.200909-1434OC","volume":"181","author":"T Bienvenu","year":"2010","unstructured":"Bienvenu, T. et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 181, 1078\u201384 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"26_CR55","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1513\/AnnalsATS.201805-325RL","volume":"16","author":"K Teerapuncharoen","year":"2019","unstructured":"Teerapuncharoen, K. et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction and radiographic bronchiectasis in current and former smokers: a cross-sectional study. Ann. Am. Thorac. Soc. 16, 150\u2013153 (2019).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"26_CR56","unstructured":"Swenson CE, H. W. et al. Treating non-cystic fibrosis bronchiectasis with CFTR modulators: early case reports. Ann. Case Rep. 9, 101910 (2021)."},{"key":"26_CR57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.wjorl.2018.09.001","volume":"4","author":"C Banks","year":"2018","unstructured":"Banks, C., Freeman, L., Cho, D. Y. & Woodworth, B. A. Acquired cystic fibrosis transmembrane conductance regulator dysfunction. World J. Otorhinolaryngol. Head Neck Surg. 4, 193\u2013199 (2018).","journal-title":"World J. Otorhinolaryngol. Head Neck Surg."},{"key":"26_CR58","first-page":"78","volume":"79","author":"DY Cho","year":"2016","unstructured":"Cho, D. Y. & Woodworth, B. A. Acquired cystic fibrosis transmembrane conductance regulator deficiency. Adv. Otorhinolaryngol. 79, 78\u201385 (2016).","journal-title":"Adv. Otorhinolaryngol."},{"key":"26_CR59","first-page":"114","volume":"70","author":"X Wang","year":"2011","unstructured":"Wang, X. & Cutting, G. R. Chronic rhinosinusitis. Adv. Otorhinolaryngol. 70, 114\u2013121 (2011).","journal-title":"Adv. Otorhinolaryngol."},{"key":"26_CR60","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/archotol.131.3.237","volume":"131","author":"X Wang","year":"2005","unstructured":"Wang, X., Kim, J., McWilliams, R. & Cutting, G. R. Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation. Arch. Otolaryngol. Head Neck Surg. 131, 237\u201340 (2005).","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"26_CR61","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.284.14.1814","volume":"284","author":"X Wang","year":"2000","unstructured":"Wang, X. et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA284, 1814\u20139 (2000).","journal-title":"JAMA"},{"key":"26_CR62","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.1542\/peds.109.1.e13","volume":"109","author":"V Raman","year":"2002","unstructured":"Raman, V., Clary, R., Siegrist, K. L., Zehnbauer, B. & Chatila, T. A. Increased prevalence of mutations in the cystic fibrosis transmembrane conductance regulator in children with chronic rhinosinusitis. Pediatrics 109, E13 (2002).","journal-title":"Pediatrics"},{"issue":"Suppl 7","key":"26_CR63","first-page":"S1","volume":"125","author":"BA Woodworth","year":"2015","unstructured":"Woodworth, B. A. Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-Induced model of acquired CFTR deficiency. Laryngoscope 125(Suppl 7), S1\u2013s13 (2015).","journal-title":"Laryngoscope"},{"key":"26_CR64","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/alr.21975","volume":"7","author":"KE Tipirneni","year":"2017","unstructured":"Tipirneni, K. E. et al. Assessment of acquired mucociliary clearance defects using micro-optical coherence tomography. Int. Forum. Allergy Rhinol. 7, 920\u2013925 (2017).","journal-title":"Int. Forum. Allergy Rhinol."},{"key":"26_CR65","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/lary.23278","volume":"122","author":"NS Alexander","year":"2012","unstructured":"Alexander, N. S. et al. Cystic fibrosis transmembrane conductance regulator modulation by the tobacco smoke toxin acrolein. Laryngoscope 122, 1193\u20137 (2012).","journal-title":"Laryngoscope"},{"key":"26_CR66","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2500\/ajra.2011.25.3643","volume":"25","author":"S Zhang","year":"2011","unstructured":"Zhang, S. et al. Quercetin increases cystic fibrosis transmembrane conductance regulator-mediated chloride transport and ciliary beat frequency: therapeutic implications for chronic rhinosinusitis. Am. J. Rhinol. Allergy 25, 307\u201312 (2011).","journal-title":"Am. J. Rhinol. Allergy"},{"key":"26_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.101998","volume":"43","author":"DY Cho","year":"2021","unstructured":"Cho, D. Y. et al. LPS decreases CFTR open probability and mucociliary transport through generation of reactive oxygen species. Redox. Biol. 43, 101998 (2021).","journal-title":"Redox. Biol."},{"key":"26_CR68","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1096\/fj.11-192377","volume":"26","author":"LA Clunes","year":"2012","unstructured":"Clunes, L. A. et al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway surface liquid dehydration. Faseb J. 26, 533\u201345 (2012).","journal-title":"Faseb J."},{"key":"26_CR69","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1378\/chest.13-0274","volume":"144","author":"MT Dransfield","year":"2013","unstructured":"Dransfield, M. T. et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest 144, 498\u2013506 (2013).","journal-title":"Chest"},{"key":"26_CR70","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/lary.20930","volume":"120","author":"FW Virgin","year":"2010","unstructured":"Virgin, F. W. et al. Exposure to cigarette smoke condensate reduces calcium activated chloride channel transport in primary sinonasal epithelial cultures. Laryngoscope 120, 1465\u20139 (2010).","journal-title":"Laryngoscope"},{"key":"26_CR71","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1183\/09031936.00228013","volume":"44","author":"MA Mall","year":"2014","unstructured":"Mall, M. A. & Hartl, D. CFTR: cystic fibrosis and beyond. Eur. Respir. J. 44, 1042\u201354 (2014).","journal-title":"Eur. Respir. J."},{"key":"26_CR72","doi-asserted-by":"publisher","first-page":"e39809","DOI":"10.1371\/journal.pone.0039809","volume":"7","author":"PA Sloane","year":"2012","unstructured":"Sloane, P. A. et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS One 7, e39809 (2012).","journal-title":"PLoS One"},{"key":"26_CR73","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jaip.2023.12.016","volume":"12","author":"JN Palmer","year":"2024","unstructured":"Palmer, J. N. et al. Efficacy of EDS-FLU for Chronic rhinosinusitis: two randomized controlled trials (ReOpen1 and ReOpen2). J. Allergy Clin. Immunol. Pract. 12, 1049\u20131061 (2024).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"26_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49544-9","volume":"9","author":"AJ Marklew","year":"2019","unstructured":"Marklew, A. J. et al. Cigarette smoke exposure induces retrograde trafficking of CFTR to the endoplasmic reticulum. Sci. Rep. 9, 13655 (2019).","journal-title":"Sci. Rep."},{"key":"26_CR75","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1021\/acsmedchemlett.3c00155","volume":"14","author":"A Rab","year":"2023","unstructured":"Rab, A. et al. A Novel 7H-[1,2,4]Triazolo[3,4-b]thiadiazine-based cystic fibrosis transmembrane conductance regulator potentiator directed toward treatment of cystic fibrosis. ACS Med. Chem. Lett 14, 1338\u20131343 (2023).","journal-title":"ACS Med. Chem. Lett"},{"key":"26_CR76","unstructured":"Cell_Model_Resources. Cell Model Resources. https:\/\/www.cff.org\/researchers\/cell-model-resources (2021)."},{"key":"26_CR77","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1021\/acschembio.7b00903","volume":"13","author":"JB Baell","year":"2018","unstructured":"Baell, J. B. & Nissink, J. W. M. Seven year itch: pan-assay interference compounds (PAINS) in 2017-utility and limitations. ACS Chem. Biol. 13, 36\u201344 (2018).","journal-title":"ACS Chem. Biol."},{"key":"26_CR78","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey, B. W. et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663\u201372 (2011).","journal-title":"N. Engl. J. Med."},{"key":"26_CR79","doi-asserted-by":"crossref","unstructured":"Solomon, G. M. et al. Elexacaftor-Tezacaftor-Ivacaftor improves clinical outcomes in individuals with CF encoding N1303K CFTR. Lancet Respir. Med. 27, s2213\u22122600 (2024).","DOI":"10.2139\/ssrn.4745080"},{"key":"26_CR80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2409049121","volume":"121","author":"K Fiedorczuk","year":"2024","unstructured":"Fiedorczuk, K. et al. The structures of protein kinase A in complex with CFTR: Mechanisms of phosphorylation and noncatalytic activation. Proc. Natl. Acad. Sci. USA 121, e2409049121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"26_CR81","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.bbamem.2009.03.015","volume":"1788","author":"T Hegedus","year":"2009","unstructured":"Hegedus, T. et al. Role of individual R domain phosphorylation sites in CFTR regulation by protein kinase A. Biochim. Biophys. Acta.1788, 1341\u20139 (2009).","journal-title":"Biochim. Biophys. Acta."},{"key":"26_CR82","doi-asserted-by":"crossref","unstructured":"Murabito, A., Bhatt, J. & Ghigo, A. It Takes Two to Tango! Protein-Protein Interactions behind cAMP-Mediated CFTR Regulation. Int. J. Mol. Sci. 24, 10538 (2023).","DOI":"10.3390\/ijms241310538"},{"key":"26_CR83","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1242\/jcs.089086","volume":"125","author":"S Monterisi","year":"2012","unstructured":"Monterisi, S. et al. CFTR regulation in human airway epithelial cells requires integrity of the actin cytoskeleton and compartmentalized cAMP and PKA activity. J. Cell Sci. 125, 1106\u201317 (2012).","journal-title":"J. Cell Sci."},{"key":"26_CR84","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1513\/pats.2306012","volume":"1","author":"P Huang","year":"2004","unstructured":"Huang, P. et al. Local regulation of cystic fibrosis transmembrane regulator and epithelial sodium channel in airway epithelium. Proc. Am. Thorac. Soc. 1, 33\u20137 (2004).","journal-title":"Proc. Am. Thorac. Soc."},{"key":"26_CR85","doi-asserted-by":"publisher","first-page":"7997","DOI":"10.1074\/jbc.M407521200","volume":"280","author":"AP Barnes","year":"2005","unstructured":"Barnes, A. P. et al. Phosphodiesterase 4D forms a cAMP diffusion barrier at the apical membrane of the airway epithelium. J. Biol. Chem. 280, 7997\u20138003 (2005).","journal-title":"J. Biol. Chem."},{"key":"26_CR86","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/jamp.2011.0942","volume":"26","author":"J Ruddy","year":"2013","unstructured":"Ruddy, J. et al. Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin. J. Aerosol. Med. Pulm Drug Deliv. 26, 69\u201375 (2013).","journal-title":"J. Aerosol. Med. Pulm Drug Deliv."},{"key":"26_CR87","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jcf.2009.07.001","volume":"8","author":"D Hubert","year":"2009","unstructured":"Hubert, D. et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. J. Cyst. Fibros 8, 332\u20137 (2009).","journal-title":"J. Cyst. Fibros"},{"key":"26_CR88","doi-asserted-by":"crossref","unstructured":"van Goor, F., Hadida S., Grootenhuis, P. Pharmacological rescue of mutant CFTR function for the treatment of cystic fibrosis. In Ion Channels. Topics in Medicinal Chemistry, (ed. Fermini, B., Priest, B. T.) 3 (Springer, Berlin, Heidelberg, 2008).","DOI":"10.1007\/7355_2008_022"},{"key":"26_CR89","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","volume":"13","author":"F Van Goor","year":"2014","unstructured":"Van Goor, F., Yu, H., Burton, B. & Hoffman, B. J. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J. Cyst. Fibros 13, 29\u201336 (2014).","journal-title":"J. Cyst. Fibros"},{"key":"26_CR90","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1172\/JCI118819","volume":"98","author":"TJ Kelley","year":"1996","unstructured":"Kelley, T. J., Al-Nakkash, L., Cotton, C. U. & Drumm, M. L. Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J. Clin. Invest. 98, 513\u201320 (1996).","journal-title":"J. Clin. Invest."},{"key":"26_CR91","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1091\/mbc.e09-08-0655","volume":"21","author":"H Penmatsa","year":"2010","unstructured":"Penmatsa, H. et al. Compartmentalized cyclic adenosine 3\u2019,5\u2019-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains. Mol. Biol. Cell 21, 1097\u2013110 (2010).","journal-title":"Mol. Biol. Cell"},{"key":"26_CR92","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1124\/jpet.105.083519","volume":"314","author":"S Liu","year":"2005","unstructured":"Liu, S. et al. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 314, 846\u201354 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"26_CR93","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1152\/physrev.1999.79.1.S109","volume":"79","author":"BD Schultz","year":"1999","unstructured":"Schultz, B. D., Singh, A. K., Devor, D. C. & Bridges, R. J. Pharmacology of CFTR chloride channel activity. Physiol. Rev. 79, S109\u201344 (1999).","journal-title":"Physiol. Rev."},{"key":"26_CR94","doi-asserted-by":"publisher","first-page":"L12","DOI":"10.1152\/ajplung.2002.282.1.L12","volume":"282","author":"BR Cobb","year":"2002","unstructured":"Cobb, B. R. et al. A(2) adenosine receptors regulate CFTR through PKA and PLA(2). Am. J. Physiol. Lung Cell Mol. Physiol. 282, L12\u201325 (2002).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"26_CR95","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1096\/fj.13-240861","volume":"28","author":"E Blanchard","year":"2014","unstructured":"Blanchard, E. et al. Anchored PDE4 regulates chloride conductance in wild-type and \u0394F508-CFTR human airway epithelia. Faseb J. 28, 791\u2013801 (2014).","journal-title":"Faseb J."},{"key":"26_CR96","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.pupt.2010.02.001","volume":"23","author":"SM Rowe","year":"2010","unstructured":"Rowe, S. M. et al. DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol. Ther. 23, 268\u201378 (2010).","journal-title":"Pulm Pharmacol. Ther."},{"key":"26_CR97","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1165\/rcmb.2002-0247OC","volume":"29","author":"BR Cobb","year":"2003","unstructured":"Cobb, B. R., Fan, L., Kovacs, T. E., Sorscher, E. J. & Clancy, J. P. Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am. J. Respir. Cell Mol. Biol. 29, 410\u20138 (2003).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"26_CR98","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2020.00259","volume":"11","author":"JE Phillips","year":"2020","unstructured":"Phillips, J. E. Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases. Front Pharmacol. 11, 259 (2020).","journal-title":"Front Pharmacol."},{"key":"26_CR99","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pharmthera.2019.02.002","volume":"197","author":"H Zuo","year":"2019","unstructured":"Zuo, H., Cattani-Cavalieri, I., Musheshe, N., Nikolaev, V. O. & Schmidt, M. Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol. Ther. 197, 225\u2013242 (2019).","journal-title":"Pharmacol. Ther."},{"key":"26_CR100","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1124\/jpet.120.000080","volume":"375","author":"MJ Turner","year":"2020","unstructured":"Turner, M. J., Dauletbaev, N., Lands, L. C. & Hanrahan, J. W. The phosphodiesterase inhibitor ensifentrine reduces production of proinflammatory mediators in well differentiated bronchial epithelial cells by inhibiting PDE4. J. Pharmacol. Exp. Ther. 375, 414\u2013429 (2020).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"26_CR101","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S2213-2600(18)30331-X","volume":"6","author":"KF Rabe","year":"2018","unstructured":"Rabe, K. F. et al. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16\u2009week, randomised, placebo-controlled trial. Lancet Respir. Med. 6, 827\u2013836 (2018).","journal-title":"Lancet Respir. Med."},{"key":"26_CR102","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/13543784.2019.1661990","volume":"28","author":"M Cazzola","year":"2019","unstructured":"Cazzola, M., Calzetta, L., Rogliani, P. & Matera, M. G. Ensifentrine (RPL554): an investigational PDE3\/4 inhibitor for the treatment of COPD. Expert. Opin. Investig. Drugs 28, 827\u2013833 (2019).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"26_CR103","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cyto.2018.06.007","volume":"113","author":"T Southworth","year":"2019","unstructured":"Southworth, T. et al. Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients. Cytokine 113, 68\u201373 (2019).","journal-title":"Cytokine"},{"key":"26_CR104","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12931-020-1329-y","volume":"21","author":"M Govoni","year":"2020","unstructured":"Govoni, M. et al. Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis. Respir. Res. 21, 72 (2020).","journal-title":"Respir. Res."},{"key":"26_CR105","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3389\/fphar.2020.01266","volume":"11","author":"I Yougbare","year":"2020","unstructured":"Yougbare, I. et al. NCS 613, a potent PDE4 inhibitor, displays anti-inflammatory and anti-proliferative properties on A549 lung epithelial cells and human lung adenocarcinoma explants. Front Pharmacol. 11, 1266 (2020).","journal-title":"Front Pharmacol."},{"key":"26_CR106","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1753425918809155","volume":"24","author":"JX Yang","year":"2018","unstructured":"Yang, J. X. et al. Synergistic effect of phosphodiesterase 4 inhibitor and serum on migration of endotoxin-stimulated macrophages. Innate. Immun. 24, 501\u2013512 (2018).","journal-title":"Innate. Immun."},{"key":"26_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154739","volume":"123","author":"S Lea","year":"2019","unstructured":"Lea, S. et al. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients. Cytokine 123, 154739 (2019).","journal-title":"Cytokine"},{"key":"26_CR108","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1091\/mbc.e12-06-0424","volume":"23","author":"G Veit","year":"2012","unstructured":"Veit, G. et al. Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia. Mol. Biol. Cell 23, 4188\u2013202 (2012).","journal-title":"Mol. Biol. Cell"},{"key":"26_CR109","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3904\/kjim.2020.035","volume":"35","author":"CK Rhee","year":"2020","unstructured":"Rhee, C. K. & Kim, D. K. Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease. Korean J. Intern. Med. 35, 276\u2013283 (2020).","journal-title":"Korean J. Intern. Med."},{"key":"26_CR110","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/COPD.S89849","volume":"11","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha, J. A., Calverley, P. M. & Rabe, K. F. Roflumilast: a review of its use in the treatment of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 11, 81\u201390 (2016).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"26_CR111","unstructured":"Lennon, K. FDA Approves Starting Dose of Roflumilast. https:\/\/www.mdedge.com\/content\/fda-approves-starting-dose-roflumilast (2018)."},{"key":"26_CR112","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12931-020-01512-y","volume":"21","author":"D Singh","year":"2020","unstructured":"Singh, D. et al. Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study. Respir. Res. 21, 246 (2020).","journal-title":"Respir. Res."},{"key":"26_CR113","unstructured":"Study to evaluate the efficacy and safety of two doses of CHF6001 DPI (Tanimilast) as add-on to maintenance triple therapy in subjects with COPD and chronic bronchitis (PILLAR). (Good Clinical Practice Network)."},{"key":"26_CR114","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/jcmm.16146","volume":"25","author":"D Singh","year":"2021","unstructured":"Singh, D. et al. COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type-2 and PDE4 gene expression in sputum. J. Cell Mol. Med. 25, 905\u2013918 (2021).","journal-title":"J. Cell Mol. Med."},{"key":"26_CR115","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12931-019-1142-7","volume":"20","author":"D Singh","year":"2019","unstructured":"Singh, D. et al. Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. Respir. Res. 20, 180 (2019).","journal-title":"Respir. Res."},{"key":"26_CR116","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.2147\/COPD.S174156","volume":"13","author":"F Mariotti","year":"2018","unstructured":"Mariotti, F., Govoni, M., Lucci, G., Santoro, D. & Nandeuil, M. A. Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers. Int. J. Chron. Obstruct. Pulmon. Dis. 13, 3399\u20133410 (2018).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"26_CR117","first-page":"PA4086","volume":"48","author":"G Lucci","year":"2016","unstructured":"Lucci, G. et al. Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers. Eur. Resp. J. 48, PA4086 (2016).","journal-title":"Eur. Resp. J."},{"key":"26_CR118","unstructured":"PracticeUpdate. ATS 2019: the novel inhaled PDE4 inhibitor CHF6001 shows promise in moderate to severe COPD and chronic bronchitis. (Respiratory Medicine, 2019)."},{"key":"26_CR119","unstructured":"GlobeNewswire. Verona Pharma announces US FDA approval of Ohtuvayre (ensifentrine). https:\/\/www.globenewswire.com\/newsrelease\/2024\/06\/26\/2904839\/0\/en\/Verona-Pharma-Announces-US-FDA-Approval-of-Ohtuvayre-ensifentrine.html (2024)."},{"key":"26_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107826","volume":"224","author":"MJ Turner","year":"2021","unstructured":"Turner, M. J., Abbott-Banner, K., Thomas, D. Y. & Hanrahan, J. W. Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis. Pharmacol. Ther. 224, 107826 (2021).","journal-title":"Pharmacol. Ther."},{"key":"26_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79555-w","volume":"11","author":"JP Nguyen","year":"2021","unstructured":"Nguyen, J. P. et al. Modulation of cAMP metabolism for CFTR potentiation in human airway epithelial cells. Sci. Rep.11, 904 (2021).","journal-title":"Sci. Rep."},{"key":"26_CR122","doi-asserted-by":"publisher","first-page":"L908","DOI":"10.1152\/ajplung.00285.2019","volume":"318","author":"MJ Turner","year":"2020","unstructured":"Turner, M. J., Luo, Y., Thomas, D. Y. & Hanrahan, J. W. The dual phosphodiesterase 3\/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants. Am. J. Physiol. Lung Cell Mol. Physiol. 318, L908\u2013l920 (2020).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"26_CR123","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jcf.2023.03.004","volume":"22","author":"E de Poel","year":"2023","unstructured":"de Poel, E. et al. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes. J. Cyst. Fibros 22, 548\u2013559 (2023).","journal-title":"J. Cyst. Fibros"},{"key":"26_CR124","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1113\/jphysiol.2005.096669","volume":"569","author":"Z Bebok","year":"2005","unstructured":"Bebok, Z. et al. Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o- airway epithelial monolayers. J. Physiol. 569, 601\u201315 (2005).","journal-title":"J. Physiol."},{"key":"26_CR125","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1073\/pnas.91.11.5192","volume":"91","author":"LS Prince","year":"1994","unstructured":"Prince, L. S., Workman, R. B. Jr & Marchase, R. B. Rapid endocytosis of the cystic fibrosis transmembrane conductance regulator chloride channel. Proc. Natl. Acad. Sci. USA 91, 5192\u20136 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["npj Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44386-025-00026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-025-00026-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-025-00026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:03:01Z","timestamp":1762149781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44386-025-00026-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":125,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26"],"URL":"https:\/\/doi.org\/10.1038\/s44386-025-00026-1","relation":{},"ISSN":["3005-1452"],"issn-type":[{"value":"3005-1452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Sorscher serves as a non-voting member of the Cystic Fibrosis Foundation Board of Trustees and is Chair of the Foundation\u2019s Medical Advisory Council, both unpaid positions. The Foundation had no participation in the preparation of this manuscript or the research reported herein. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}